[Establishment of Blinatumomab Home Administration Transition Program Using CADD-Legacy® Pump]

Area of Science:

• Pediatric Oncology
• Pharmacology
• Patient Care Management

Context:

• Blinatumomab administration requires specialized care, often necessitating hospitalization.
• Transitioning pediatric patients from inpatient to home care presents unique challenges.
• The CADD-Legacy pump is a key device for continuous drug delivery.

Purpose:

• To establish and evaluate a safe and feasible transition program for home administration of blinatumomab in pediatric patients.
• To assess the role of repeated overnight hospital stays in facilitating this transition.
• To determine the conditions under which outpatient or school-based administration is viable.

Summary:

• A transition program was developed for home blinatumomab administration using the CADD-Legacy pump.
• The program incorporates repeated overnight hospital stays to ensure patient safety during the transition.
• Education for caregivers and school personnel is crucial for successful outpatient or school-based administration, particularly for non-attending or returning students.

Impact:

• This program offers a potential pathway to reduce hospital stays and improve quality of life for pediatric patients on blinatumomab.
• Successful home administration can lead to more normalized routines for children, including school attendance.
• The findings support the development of similar transition programs for other complex home-based therapies in pediatric oncology.